TGFB1 and neoplasm: TGFB1 can also enhance PD-L1 expression and treatment with a TGF-β1 receptor kinase inhibitor can downregulate PD-L1 expression in head and neck cancer, suggesting that targeting the EMT process could reverse the immunosuppressive tumor microenvironment [27].